Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Keratosis, Actinic 2Skin Diseases 1Precancerous Conditions 1Keratosis 1

Interventions

Biopsy 3Microarray Analysis 2Methylprednisolone 2Filgrastim 2Cyclophosphamide 2Colposcopy 2Carboplatin 2sargramostim 1pyroxamide 1pirfenidone 1human papillomavirus vaccine, TA 1artemisinin 1arginine butyrate 1Zoledronic Acid 1Video-Assisted Surgery 1Topotecan 1Tetradecanoylphorbol Acetate 1Tacrolimus 1Sodium Chloride 1Radiotherapy 1Prednisone 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Light Coagulation 1Leucovorin 1Interleukin-12 Subunit p35 1Interferon-alpha 1Inositol 1Immunoenzyme Techniques 1Imiquimod 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Precancerous Conditions × BF-200 ALA × Clear all
NCT05060237 2024-10-17

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Biofrontera Bioscience GmbH

Phase 1 Completed
112 enrolled 21 charts
DermatologicOther neoplasm

Keratosis, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡